
|Articles|August 24, 2015
Dr. Tripathy on the Development of Palbociclib in Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.
Advertisement
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Pirtobrutinib Wins Traditional FDA Approval in CLL and SLL
2
Which Cancer Therapies Were Approved by the FDA in November?
3
FDA Approves Liso-Cel in Pretreated R/R Marginal Zone Lymphoma
4
Rx Road Map: Adagrasib With Cetuximab for KRAS G12C-Mutated mCRC
5

















































































